What is Sweetch?
Founded in 2013, Sweetch operates at the intersection of behavioral science, AI, and emotional intelligence to foster continuous patient engagement. Its clinically validated digital therapeutics platform is designed for pharmaceutical companies, device manufacturers, payers, and healthcare providers. Sweetch's core offering enables these entities to build and maintain relationships with individual patients managing chronic conditions at scale, providing hyper-personalized recommendations tailored to the patient's health journey, delivered at the optimal time and in the appropriate context.
How much funding has Sweetch raised?
Sweetch has raised a total of $20M across 1 funding round:
Series A
$20M
Series A (2021): $20M with participation from Tal-Cap, Noaber, Kortex Ventures, FinTLV Ventures, and Entree Capital
Key Investors in Sweetch
Tal-Cap
Tal-Cap, Inc. is a company focused on acquiring viable businesses, suggesting a strategic interest in Sweetch's market potential.
Entree Capital
Entree Capital is a venture capital firm that partners with technology and product businesses from early stages through scale-up, providing capital and strategic guidance.
Noaber
Noaber is an investor participating in Sweetch's funding round, indicating a belief in the company's innovative approach to chronic condition management.
What's next for Sweetch?
The recent major strategic investment signals a pivotal moment for Sweetch, likely enabling the company to accelerate product development, expand its market penetration, and enhance its AI and EI capabilities. This infusion of capital is expected to fuel further innovation in its hyper-personalized engagement solutions, solidifying its role as a key player in the digital health and chronic condition management landscape. The company's focus on building continuous relationships at scale positions it for substantial growth and impact within the enterprise healthcare ecosystem.
See full Sweetch company page
